Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Shinhan Financial Group Q1 2026 Earnings Call - Shinhan Upgrades Value Plan to 3.0 Plus, Targets 10%+ ROE with 50%+ Shareholder Return
Shinhan Financial Group reported a 9% year-over-year jump in Q1 2026 net income to KRW 1.62 trillion, driven by a 26.5% surge in non-interest income, particularly brokerage fees and fund sales, as cap...
- Q1 2026 net income rose 9% year-over-year to KRW 1.62 trillion, supported by a 26.5% increase in non-interest income, particularly brokerage fees (+215.2% YoY) and fund/bancassurance fees (+54.7% YoY).
- Shinhan Financial Group unveiled Shinhan Value Up 3.0 Plus, replacing its prior 10/50/50 targets with a sustainable framework focused on achieving a 10%+ ROE, 50%+ total shareholder return ratio, and maintaining a CET1 ratio above 13%.
- The group’s CET1 ratio stood at 13.19% at end-Q1, declining 68 basis points due to RWA growth and shareholder returns, but only 16 basis points from year-end, reflecting stable capital management.
- +7 more takeaways
Angel Studios Q1 2026 Earnings Call - Positive Adjusted EBITDA Driven by 72% Guild Revenue Mix
Angel Studios delivered a transformative Q1 2026, posting $115 million in revenue and $4 million in positive Adjusted EBITDA, a stark reversal from the $28 million loss in the prior year. The company’...
- Total revenue surged 143% year-over-year to $115 million, driven by a rapid shift toward recurring membership income.
- Adjusted EBITDA flipped to positive $4 million, a $32 million improvement from a $28 million loss in Q1 2025.
- The Angel Guild now represents 72% of total revenue, up from 63% in Q4 2025, signaling successful monetization of the community model.
- +7 more takeaways
Myomo Inc Q1 2026 Earnings Call - Recurring Revenue Shift and Operating Leverage Drive Profitability
Myomo Inc (MYO) delivered a first quarter that validated its strategic pivot from high-cost direct-to-patient marketing toward a recurring referral model anchored by the MyoConnect program and strateg...
- Revenue reached $10.1 million, up 3% year-over-year, driven by a 9% increase in average selling price to $58,800, partially offset by a slight decline in revenue units delivered.
- The company successfully shifted its revenue mix, with recurring patient sources accounting for 49% of Q1 revenue, a significant jump from 25% in the prior year quarter.
- Operating expenses decreased 1% year-over-year to $10.1 million, while gross margin expanded by 100 basis points to 68.2%, demonstrating early operating leverage.
- +7 more takeaways
Insight Molecular Diagnostics Q1 2026 Earnings Call - GraftAssureDx FDA Review Gains Momentum, Q2 Cash Burn Peaks at $9M
Insight Molecular Diagnostics is advancing its GraftAssureDx submission to the FDA with active engagement and expects first U.S. orders later this year. The company is building a self-funding GALACTIC...
- GraftAssureDx is in active FDA review with high engagement; first U.S. orders expected later this year.
- GALACTIC Registry enrollment has grown to 34 U.S. centers, up from 28 in six weeks, nearing the 50-center goal.
- GraftAssureCore is reimbursed by Medicare at $2,753 per result, providing a clear pricing anchor for commercial strategy.
- +7 more takeaways
Aeluma Q3 FY2026 Earnings Call - AI Datacom Demand Surges as Indium Phosphide Bottlenecks Fuel Aeluma's Non-IP Strategy
Aeluma's Q3 FY2026 results reflect a company navigating the intersection of near-term supply chain pain and long-term technological disruption. Revenue dipped slightly to $1.2 million, weighed down by...
- Revenue for Q3 FY2026 was $1.2 million, down from $1.3 million in the prior year and quarter, primarily due to delayed government contract starts.
- GAAP net loss was $1.8 million, or $0.10 per share, compared to a net income of $1.5 million in the prior year period, largely due to a one-time $2.3 million gain in derivative liabilities recorded in Q3 FY2025.
- Non-GAAP net loss was $701,000, or $0.04 per share, in line with the prior quarter, while adjusted EBITDA loss widened to $911,000 from a $109,000 gain in the prior year.
- +7 more takeaways
Sangoma Technologies Q3 FY2026 Earnings Call - Infrastructure Pivot and Strategic Review Accelerate Amid Market Shift
Sangoma Technologies is in a deliberate pivot, shifting capital and focus from a commoditizing UCaaS software business toward its growing voice and data networking infrastructure. Management highlight...
- Sangoma is redefining its business model, shifting focus from commoditized UCaaS applications to high-growth voice and data networking infrastructure, which is now the primary engine for value creation.
- Full-year FY2026 revenue guidance is lowered to CAD 204-205 million, reflecting international geopolitical disruptions, shipping cost inflation, and pricing pressure in software markets.
- The board has initiated a formal strategic review to evaluate all alternatives, including potential M&A or sale, driven by persistent market undervaluation and increased inbound interest.
- +9 more takeaways
CXAI (SKY) Q1 2026 Earnings Call - Agentic AI Wins Drive Enterprise Momentum Despite Revenue Dip
CXAI (SKY) reported a slight Q1 2026 revenue decline to $950K, but the real story lies in the surge of high-quality enterprise bookings. The company closed three multi-year deals worth $5 million in t...
- Revenue dipped to $950K in Q1 2026 from $1.02M in Q4, primarily due to the timing of new deal closures and enterprise revenue recognition patterns.
- Bookings surged to $1.4M, a 12.5% year-over-year increase, beating internal forecasts by 19% and signaling strong future revenue potential.
- Three new multi-year enterprise deals were closed, representing approximately $5 million in total contract value, with a focus on large financial services clients.
- +12 more takeaways
STAAR Surgical Q1 2026 Earnings Call - China Momentum and Margin Turnaround Drive Profitability
STAAR Surgical delivered a sharp turnaround in Q1 2026, with net sales surging 120% year-over-year to $93.5 million. The growth was almost entirely fueled by a strong recovery in China, where normaliz...
- Net sales surged 120% year-over-year to $93.5 million, driven by a massive recovery in China and double-digit growth in the Americas.
- Adjusted EBITDA turned positive at $24.4 million, a sharp reversal from a $26.3 million loss in the prior year quarter.
- Gross profit margin expanded significantly to 73.6%, up from 65.8% a year ago, aided by lower inventory provisions and reduced manufacturing ramp-up costs.
- +7 more takeaways
Tamboran Resources Q3 FY2026 Earnings Call - Beetaloo Pilot Nears First Gas as $28.5M Farm-Out Rerates Basin Value
Tamboran Resources is advancing rapidly toward first gas from its Beetaloo Basin pilot project, with construction on the Sturt Plateau Compression Facility at 88% completion and first gas targeted for...
- Tamboran Resources targets first gas from its Beetaloo Basin pilot area in Q3 calendar 2026, with the Sturt Plateau Compression Facility construction 88% complete and tracking within P50 budget and schedule.
- The company executed a farm-out transaction with Daly Waters Energy, transferring ~10,000 acres for a staged carry of up to $28.5 million, establishing a valuation benchmark mirroring a recent Inpex deal.
- Post-transaction, Tamboran retains a 44.375% interest in the pilot area and a 10% interest in the Daly Waters acreage, while maintaining an active joint venture on the Orion Block.
- +7 more takeaways
StubHub Q1 2026 Earnings Call - Margin Expansion and Open Distribution Push Drive Profitability
StubHub delivered a strong first quarter in 2026, with GMS growing 7% to $2.2 billion and adjusted EBITDA margin expanding 400 basis points to 16%. The company is capitalizing on its market leadership...
- GMS grew 7% year-over-year to $2.2 billion, driven by North American resale growth, market share leadership, and international expansion.
- Adjusted EBITDA margin expanded 400 basis points to 16%, reflecting normalized revenue conversion, improved gross margins, and marketing efficiency.
- Sales and marketing expense fell to 50% of revenue, a 500 basis point improvement year-over-year, as the company leverages scale.
- +9 more takeaways